Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical
cancer cases are caused by persistent genital high-risk human papillomavirus (HPV) …

Background Only clinically validated HPV assays can be accepted in cervical cancer
screening. Objectives To update the list of high-risk HPV assays that fulfil the 2009 …

Cervical cancer is one of the leading causes of cancer death among females worldwide and
its behavior epidemiologically likes a venereal disease of low infectiousness. Early age at …

Objective To evaluate the diagnostic accuracy of high-risk human papillomavirus (hrHPV)
assays on self samples and the efficacy of self sampling strategies to reach underscreened …

Background Screening for human papillomavirus (HPV) infection is more effective in
reducing the incidence of cervical cancer than screening using Pap smears. Moreover, HPV …

Background Coinciding with the release of the first Chinese domestic human papillomavirus
(HPV) vaccine Cecolin in 2019, and the substantial advancements in cervical cancer …

More than ever, clinicians need regularly updated reviews given the continuously increasing
amount of new information regarding innovative cervical cancer prevention methods. A …

Genotyping may improve risk stratification of high‐risk (HR) human papillomavirus (HPV)‐
positive women in cervical screening programs; however, prospective data comparing the …

Background The knowledge that persistent human papillomavirus infection is the main
cause of cervical cancer has resulted in the development of assays that detect nucleic acids …

Strong evidence now supports the adoption of cervical cancer prevention strategies that
explicitly focus on persistent infection with the causal agent, human papillomavirus (HPV) …